Sight Sciences Inc
NASDAQ:SGHT
Intrinsic Value
Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. [ Read More ]
The intrinsic value of one SGHT stock under the Base Case scenario is 7.73 USD. Compared to the current market price of 5.14 USD, Sight Sciences Inc is Undervalued by 33%.
Valuation Backtest
Sight Sciences Inc
Run backtest to discover the historical profit from buying and selling SGHT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Sight Sciences Inc
Current Assets | 162.9m |
Cash & Short-Term Investments | 138.1m |
Receivables | 14.3m |
Other Current Assets | 10.5m |
Non-Current Assets | 3.8m |
PP&E | 3.1m |
Other Non-Current Assets | 682k |
Current Liabilities | 12.3m |
Accounts Payable | 1.7m |
Accrued Liabilities | 8.3m |
Other Current Liabilities | 2.2m |
Non-Current Liabilities | 34.2m |
Long-Term Debt | 31.7m |
Other Non-Current Liabilities | 2.5m |
Earnings Waterfall
Sight Sciences Inc
Revenue
|
81.1m
USD
|
Cost of Revenue
|
-11.9m
USD
|
Gross Profit
|
69.2m
USD
|
Operating Expenses
|
-126.4m
USD
|
Operating Income
|
-57.3m
USD
|
Other Expenses
|
1.7m
USD
|
Net Income
|
-55.5m
USD
|
Free Cash Flow Analysis
Sight Sciences Inc
SGHT Profitability Score
Profitability Due Diligence
Sight Sciences Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Sight Sciences Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
SGHT Solvency Score
Solvency Due Diligence
Sight Sciences Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Sight Sciences Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SGHT Price Targets Summary
Sight Sciences Inc
According to Wall Street analysts, the average 1-year price target for SGHT is 5.74 USD with a low forecast of 5.05 USD and a high forecast of 7.35 USD.
Ownership
SGHT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SGHT Price
Sight Sciences Inc
Average Annual Return | -38.87% |
Standard Deviation of Annual Returns | 10.89% |
Max Drawdown | -97% |
Market Capitalization | 252.5m USD |
Shares Outstanding | 49 553 400 |
Percentage of Shares Shorted | 4.06% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. The company is headquartered in Menlo Park, California and currently employs 212 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company’s Surgical Glaucoma segment has a product portfolio, which features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision. Its Dry Eye segment has a product portfolio, which consists of the TearCare System for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. The company sells both systems through a direct sales model.
Contact
IPO
Employees
Officers
The intrinsic value of one SGHT stock under the Base Case scenario is 7.73 USD.
Compared to the current market price of 5.14 USD, Sight Sciences Inc is Undervalued by 33%.